NVO: Novo Nordisk A/S - Summary | Jitta

Novo Nordisk A/S

NYSE:NVO

Price
$69.97
Loss Chance
39.7%
7.75JITTA SCORE
155.49%Over Jitta Line
Jitta Ranking
40 / 939
600 / 4,286
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (59)
Recent Business Performance (79)
Financial Strength (89)
Return to Shareholders (91)
Competitive Advantage (76)
Jitta Signs
Revenue and EarningConsistent
Operating MarginConsistent
Debt LevelLow Long Term Debt
Return on EquityConsistently High
Dividend PayoutIncreasing Every Year
Share RepurchaseEvery Year
CapExVery Low
Interest Coverage RatioVery Good
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
7.75
155.49%
2.11
162.71%
2.30
292.60%
Pharmaceuticals
4.16
22.50%
6.17
54.06%
7.54
5.35%
COMPANY DESCRIPTION
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson’s diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.